recent
zika
viru
zikv
attract
much
attent
consider
associ
sever
neurolog
complic
includ
fetal
microcephali
howev
current
prophylact
vaccin
therapeut
drug
approv
clinic
treatment
zikv
infect
determin
potenti
antizikv
inhibitor
screen
librari
clinic
drug
good
safeti
profil
erythromycin
estol
eryest
one
macrolid
antibiot
found
effect
inhibit
zikv
infect
differ
cell
type
significantli
protect
mice
zikvassoci
neurolog
sign
mortal
investig
eryest
verifi
inhibit
zikv
entri
disrupt
integr
viral
membran
result
loss
zikv
infect
furthermor
eryest
also
show
inhibitori
activ
dengu
viru
denv
yellow
fever
viru
yfv
thu
eryest
may
promis
drug
patient
zikv
infect
particularli
pregnant
women
zika
viru
zikv
mosquitoborn
envelop
rna
viru
member
genu
flaviviru
flavivirida
famili
flavivirida
famili
also
contain
envelop
virus
dengu
viru
denv
yellow
fever
viru
yfv
west
nile
viru
japanes
enceph
viru
result
epidem
threaten
public
health
around
world
zikv
initi
isol
sentinel
rhesu
monkey
zika
forest
uganda
perceiv
less
harm
viru
sporad
infect
human
case
show
mild
symptom
includ
fever
malais
rash
conjunct
howev
sinc
threat
public
health
zikv
steadili
increas
due
outbreak
vari
place
yap
island
french
polynesia
micronesia
thu
zikv
recogn
emerg
arboviru
receiv
attent
global
recent
unexpect
outbreak
zikv
infect
occur
brazil
rapidli
spread
south
america
centralamerican
asian
countri
involv
million
resid
meanwhil
neurolog
disord
caus
zikv
declar
global
public
health
emerg
world
health
organ
zikv
found
associ
syndrom
epidem
french
polynesia
damag
caus
zikv
includ
sever
congenit
malform
optic
nerv
abnorm
reproduct
system
injuri
discov
recent
zikv
outbreak
microcephali
worri
abnorm
caus
zikv
fetal
neurodevelopment
defect
result
physic
learn
disabl
greatli
impact
qualiti
life
affect
children
increas
case
zikv
sexual
transmiss
multipl
harm
outcom
fetus
report
women
pregnant
tri
conceiv
regard
especi
high
risk
zikv
infect
thu
need
effect
treatment
becom
ever
press
increas
recognit
epidemiolog
pathogen
zikv
infect
urgent
develop
potent
therapi
current
vaccin
therapeut
drug
approv
treat
zikv
infect
although
great
progress
achiev
mani
potent
inhibitor
play
role
suppress
virushost
interact
membran
fusion
restrain
viral
replic
translat
disturb
autophagi
explor
identifi
vitro
vivo
howev
de
novo
develop
novel
inhibitor
requir
drug
design
valid
take
extend
amount
time
therefor
repurpos
fdaapprov
medic
pharmaceut
product
may
becom
altern
choic
provid
immedi
avail
drug
patient
mani
alreadyapprov
drug
discov
significantli
inhibit
zikv
infect
safe
use
pregnant
women
highli
toxic
thu
safeti
profil
pregnant
women
develop
zikv
inhibitor
must
consid
prioriti
determin
readytous
inhibitor
zikv
infect
screen
drug
librari
consist
fdaapprov
medic
drug
good
safeti
erythromycin
estol
eryest
could
safe
use
pregnant
women
found
inhibit
zikv
infect
effici
eryest
one
macrolid
antibiot
lauryl
sulfat
ester
propionyl
erythromycin
eri
figur
commonli
use
clinic
bacteri
infect
besid
macrolid
antibiot
studi
treat
wide
spectrum
virus
exampl
clarithromycin
macrolid
therapi
util
treat
respiratori
syncyti
viru
middl
east
respiratori
syndrom
coronaviru
merscov
infect
respect
ivermectin
azithromycin
azi
identifi
effect
inhibit
zikv
infect
best
knowledg
first
time
antizikv
activ
eryest
report
antivir
effect
vitro
vivo
also
investig
present
studi
furthermor
explor
inhibitori
mechan
eryest
zikv
vero
mg
cell
cultur
dulbecco
modifi
eagl
medium
dmem
biolog
industri
israel
fetal
bovin
serum
fb
biolog
industri
beit
haemek
israel
maintain
c
co
cell
grown
dmem
contain
fb
c
co
three
zikv
strain
genbank
flr
genbank
genbank
use
studi
origin
isol
patient
return
samoa
flr
isol
blood
human
colombia
isol
sentinel
monkey
uganda
obtain
atcc
yfv
strain
obtain
beij
tiantan
biolog
product
ltd
prepar
previous
describ
denv
ii
strain
new
guinea
c
kindli
provid
zhigang
song
shanghai
public
health
clinic
center
zikv
strain
passag
passag
flr
passag
denv
ii
strain
new
guinea
c
passag
yfv
strain
passag
use
experi
besid
zikv
strain
prepar
vero
cell
vzikv
flavivirus
use
studi
propag
cell
erythromycin
estol
eryest
erythromycin
eri
azithromycin
azi
powder
bought
santa
cruz
biotechnolog
inc
dalla
ca
usa
medchemexpress
shanghai
china
lyophil
powder
dissolv
dimethyl
sulphoxid
dmso
store
c
viral
titer
determin
plaqu
assay
perform
cell
previous
describ
cell
seed
cell
plate
incub
confluent
monolay
c
co
experi
viru
stock
sampl
serial
dilut
ad
cell
incub
h
incub
media
virus
sampl
dilut
remov
cell
infect
cell
cover
overlay
dmem
contain
fb
low
meltingpoint
lmp
agaros
promega
co
madison
wi
usa
plate
infect
cell
incub
approxim
day
fix
formaldehyd
stain
crystal
violet
plaqu
visual
titer
viru
stock
express
plaqu
form
unit
pfu
ml
vero
cell
seed
densiti
cellswel
plate
incub
c
overnight
eryest
eri
serial
dilut
dmem
contain
fb
ad
cell
incub
c
day
cell
count
dojindo
japan
use
detect
cell
vital
previous
describ
detect
use
orangecolor
formazan
could
form
catalyz
dehydrogenas
live
cell
amount
formazan
proport
number
live
cell
absorb
determin
nm
wavelength
cell
prolifer
calcul
accord
instruct
manual
drug
screen
equal
volum
zikv
strain
pfuml
compound
dilut
serumfre
dmem
final
concentr
incub
c
h
cell
infect
compoundstr
zikv
c
h
follow
replac
viral
supernat
fresh
dmem
contain
fb
zikvinduc
cytopath
effect
cpe
obviou
use
detect
antivir
activ
compound
accord
instruct
manual
evalu
antivir
efficaci
zikv
flr
denv
ii
new
guinea
c
yfv
eryest
eri
serial
dilut
serumfre
dmem
mix
pfu
virus
incub
h
c
plaqu
assay
mixtur
ad
cell
seed
cell
plate
incub
c
h
supernat
replac
dmem
contain
lmp
agaros
fb
viral
plaqu
becam
obviou
plaqu
visual
carri
describ
besid
plaqu
assay
also
use
test
inhibitori
activ
mixtur
ad
cell
seed
plate
incub
c
h
follow
replac
cultur
supernat
fresh
dmem
contain
fb
zikvinduc
cytopath
effect
cpe
obviou
use
detect
antivir
activ
accord
instruct
manual
data
collect
micropl
reader
infinit
tecan
morrisvil
nc
usa
test
inhibitori
activ
eryest
zikv
neuron
cell
mg
cell
use
briefli
eryest
eri
serial
dilut
serumfre
dmem
mix
pfu
virus
incub
h
c
mixtur
ad
mg
cell
incub
c
h
percentag
infect
cell
determin
flow
cytometri
normal
untreat
infect
cell
inhibit
eryest
zikv
multipl
round
infect
perform
previous
describ
cell
infect
pfu
zikv
treat
eryest
eri
vehicl
control
incub
c
supernat
collect
differ
timepoint
infect
zikv
titer
collect
supernat
respect
detect
plaqu
assay
addit
test
inhibitori
activ
eryest
high
viral
dose
zikv
experi
perform
multipl
infect
moi
previous
describ
briefli
cell
infect
pfu
virus
treat
eryest
eri
vehicl
control
supernat
respect
collect
h
post
infect
zikv
titer
collect
supernat
detect
plaqu
assay
pseudotyp
merscov
vesicular
stomat
viru
vsv
chosen
control
envelop
virus
prepar
previous
describ
cell
cotransfect
plasmid
encod
vsvg
protein
merscov
protein
use
vigofect
vigor
biotechnolog
beij
china
h
supernat
pseudotyp
merscov
vsv
collect
infect
cell
inhibitori
activ
eryest
virus
measur
day
luciferas
assay
system
promega
co
madison
wi
usa
confirm
inhibitori
activ
eryest
zikv
infect
vero
cell
seed
onto
coverslip
densiti
cellswel
plate
incub
h
mixtur
pfu
zikv
equal
volum
serial
dilut
eryest
eri
incub
h
c
ad
cell
h
cultur
supernat
replac
dmem
fb
day
later
cell
fix
paraformaldehyd
pfa
sigma
aldrich
st
loui
mo
usa
perfor
triton
block
bsa
amresco
llc
solon
oh
incub
anti
mab
c
overnight
wash
cell
incub
fitclabel
rabbit
antimous
igg
dako
glostrup
denmark
h
room
temperatur
wash
coverslip
seal
prolong
gold
antifad
reagent
thermo
fisher
scientif
waltham
usa
scan
leica
confoc
microscop
determin
stage
drug
display
inhibitori
effici
timeofaddit
assay
develop
previous
describ
cell
incub
c
overnight
infect
pfu
zikv
eryest
ad
infect
cell
h
post
infect
incub
c
h
supernat
replac
dmem
contain
lmp
agaros
fb
incub
approxim
day
infect
cell
fix
formaldehyd
stain
crystal
violet
plaqu
visual
entri
experi
cell
infect
zikv
presenc
eryest
c
h
follow
wash
remov
unbound
virus
drug
attach
assay
cell
infect
zikv
presenc
eryest
c
h
wash
remov
unbound
virus
drug
fusion
assay
cell
firstli
infect
zikv
c
h
allow
viral
attach
three
wash
remov
unbound
virus
eryest
ad
cell
incub
c
h
drug
remov
postentri
assay
cell
infect
zikv
c
h
allow
viral
entri
drug
ad
cell
incub
c
h
final
supernat
replac
dmem
contain
lmp
agaros
fb
incub
approxim
day
infect
cell
fix
formaldehyd
stain
crystal
violet
plaqu
visual
azi
eri
dmso
also
includ
inactiv
virion
separ
detect
previous
describ
simpli
eryest
eri
serial
dilut
mix
virus
pfu
incub
c
h
amersco
nacl
ad
mixtur
final
concentr
respect
follow
incub
ice
h
treat
virus
centrifug
h
g
c
supernat
contain
free
drug
remov
pellet
contain
viral
particl
wash
pb
contain
mg
ml
bsa
amresco
west
chester
pa
usa
centrifug
virus
pellet
resuspend
dmem
infect
viral
particl
detect
plaqu
assay
detect
genom
rna
releas
zikv
particl
rnase
digest
assay
rtqpcr
develop
previous
describ
briefli
eryest
eri
incub
zikv
pfu
c
h
releas
rna
treat
zikv
digest
micrococc
nucleas
new
england
biolab
ipswich
usa
h
c
follow
inactiv
residu
rnase
undigest
genom
rna
insid
unbroken
viru
extract
use
easypur
viral
dnarna
kit
transgen
biotech
beij
china
detect
use
transscript
ii
green
onestep
qrtpcr
supermix
transgen
biotech
beij
china
master
cycler
ep
realplex
pcr
system
eppendorf
hamburg
germani
accord
manufactur
instruct
primer
use
detect
rna
sequenc
code
viral
e
protein
follow
zikv
pfu
eryest
eri
triton
dmso
treatment
respect
without
treatment
incub
c
h
treat
untreat
zikv
gentli
load
onto
top
sucros
step
gradient
follow
centrifug
swing
bucket
rotor
beckman
coulter
brea
ca
usa
use
optima
xp
ultracentrifug
beckman
coulter
g
h
c
fraction
collect
top
bottom
detect
e
protein
western
blot
viral
genom
rna
rtqpcr
anti
mab
use
detect
e
protein
anim
experi
carri
strict
basi
ethic
guidelin
anim
welfar
act
refer
accredit
laboratori
anim
care
nation
regul
rule
relat
anim
anim
oper
protocol
approv
institut
laboratori
anim
care
use
committe
iacuc
laboratori
anim
manag
ethic
committe
shanghai
public
health
clinic
center
approv
septemb
mice
use
studi
bred
depart
laboratori
anim
scienc
shanghai
public
clinic
center
specificpathogenfre
condit
evalu
protect
effici
eryest
vivo
mice
use
previous
describ
fortyeight
mice
randomli
assign
six
group
three
group
infect
zikv
strain
intraperiton
ip
dose
pfu
mous
h
post
zikv
challeng
infect
mice
ip
administr
eryest
eri
mgkg
bodi
weight
vehicl
control
n
day
consecut
day
follow
observ
bodi
weight
clinic
syndrom
mortal
mice
deem
protect
mous
surviv
day
post
infect
dpi
viral
rna
load
sera
measur
dpi
rtqpcr
grade
clinic
sign
score
previous
describ
healthi
lethargi
inact
wast
limb
weak
hindlimb
forelimb
paralysi
tremor
moribund
death
mice
administr
heatinactiv
zikv
izikv
administr
eryest
eri
mgkg
bodi
weight
use
mock
control
anim
studi
conduct
biosafeti
level
facil
shanghai
public
health
clinic
center
institut
biosafeti
committe
approv
antivir
effici
eryest
pregnant
mice
perform
previous
describ
briefli
twenti
pregnant
mice
week
old
randomli
assign
four
virus
group
n
one
group
infect
heatinactiv
zikv
izikv
use
mock
control
three
group
ip
infect
zikv
strain
dose
pfumous
h
infect
mice
ip
administr
eryest
eri
mgkg
bodi
weight
vehicl
day
post
infect
pregnant
mice
retroorbit
bled
measur
viraemia
rtqpcr
three
embryo
mous
randomli
collect
detect
viral
rna
load
placenta
fetal
head
collect
embryo
statist
analys
carri
graphpad
prism
softwar
graphpad
prism
softwar
inc
ca
usa
logrank
mantel
cox
test
conduct
compar
surviv
curv
data
given
mean
sd
indic
p
consid
signific
n
refer
sampl
size
determin
inhibitori
activ
eryest
zikv
plaqu
assay
use
could
precis
exhibit
inhibitori
effect
eryest
eri
serial
dilut
concentr
incub
zikv
strain
c
h
treat
virus
ad
cell
report
suscept
zikv
develop
obviou
cytopath
effect
cpe
infect
zikvform
plaqu
present
visual
crystal
violet
dye
shown
figur
number
zikv
plaqu
reduc
concentr
eryest
increas
scarc
plaqu
form
eryest
treatment
plaqu
treat
eri
concentr
use
assay
gener
unchang
suggest
eryest
inhibit
zikv
infect
dosedepend
manner
inhibitori
concentr
ic
valu
eryest
zikv
plaqu
assay
figur
test
inhibitori
activ
eryest
zikv
neuron
cell
whose
damag
caus
zikv
especi
seriou
would
reduc
fetal
brain
growth
mg
cell
infect
zikv
serial
dilut
eryest
eri
treatment
found
eryest
significantli
reduc
infect
rate
mg
cell
ic
valu
figur
also
develop
immunofluoresc
stain
assay
verifi
antizikv
activ
eryest
three
differ
concentr
result
accord
data
plaqu
assay
express
zikv
e
protein
almost
complet
block
eryest
concentr
nearli
inhibit
concentr
vero
cell
figur
furthermor
cpe
zikv
vero
cell
would
make
cell
progress
necrosi
absciss
viabil
thu
could
detect
could
evalu
zikv
infect
indirectli
result
eryest
testifi
inhibit
zikv
strain
infect
ic
valu
vero
cell
respect
supplementari
figur
b
taken
togeth
data
indic
eryest
notabl
inhibit
zikv
infect
differ
cell
type
includ
neuron
cell
addit
monitor
inhibitori
activ
eryest
viral
growth
eryest
test
inhibit
zikv
infect
multistep
growth
curv
demonstr
eryest
greatli
decreas
zikv
titer
supplementari
figur
multipl
round
infect
suggest
eryest
strong
last
inhibitori
effect
zikv
infect
besid
also
shown
eryest
could
exhibit
inhibitori
activ
zikv
infect
even
rel
higher
viral
dose
figur
viral
titer
reduc
treatment
differ
concentr
eryest
treatment
eryest
decreas
viral
titer
approxim
compar
control
group
indic
eryest
remain
effect
rel
higher
dose
infect
zikv
eryest
demonstr
potent
inhibit
zikv
strain
evalu
inhibitori
activ
zikv
strain
plaqu
assay
shown
figur
b
eryest
significantli
inhibit
infect
zikv
strain
flr
ic
valu
respect
similar
strain
zikv
strain
flr
approxim
half
inhibit
micromol
eryest
suggest
eryest
could
broadli
inhibit
zikv
strain
isol
rhesu
monkey
patient
differ
area
world
follow
also
research
whether
eryest
abl
inhibit
mosquitoborn
flavivirus
denv
yfv
demonstr
eryest
potent
inhibit
infect
denv
ii
yfv
valu
respect
figur
eryest
hand
show
inhibitori
activ
envelop
virus
pseudotyp
merscov
vsv
concentr
rang
test
figur
f
rule
possibl
eryest
inhibit
zikv
prepar
mosquito
cell
test
whether
eryest
could
effect
inhibit
infect
zikv
vzikv
produc
one
kind
mammalian
cell
vero
cell
supplementari
figur
show
eryest
significantli
inhibit
figur
show
eryest
significantli
inhibit
vzikv
infect
ic
valu
similar
inhibitori
activ
zikv
propag
mosquito
cell
meanwhil
eryest
eri
low
toxic
vero
cell
figur
h
result
indic
eryest
may
effect
inhibit
flaviviru
infect
broad
spectrum
determin
step
viral
cycl
suscept
eryest
inhibit
develop
timeofaddit
experi
differ
time
point
eryest
addit
post
zikv
infect
h
post
infect
supernat
replac
maintain
medium
plaqu
assay
evalu
inhibitori
effect
eryest
differ
time
point
shown
figur
denv
ii
e
yfv
respect
treat
eryest
c
h
separ
eryest
virus
measur
infect
degrad
releas
genom
rna
zikv
treat
f
eryest
g
eri
rnase
digest
assay
genom
rna
code
e
protein
detect
separ
e
protein
zikv
treat
eryest
eri
dmso
triton
media
alon
sucros
densiti
gradient
assay
e
protein
fraction
assess
h
western
blot
percent
analyz
imag
j
softwar
calcul
genom
rna
fraction
separ
percent
total
rna
genom
measur
rtqpcr
g
experi
test
triplic
data
repres
mean
sd
experi
repeat
least
twice
similar
result
obtain
statist
analysi
unpair
student
test
b
twoway
anova
sidak
multipl
comparison
ce
oneway
anova
dunnett
multipl
comparison
f
g
ns
signific
p
p
p
p
next
confirm
particular
inhibitori
period
eryest
zikv
experi
separ
stage
go
viral
entri
postentri
stage
carri
previous
describ
azi
belong
macrolid
antibiot
well
use
experi
studi
inhibitori
mechan
differ
macrolid
antibiot
shown
figur
eryest
exhibit
obviou
inhibitori
effect
viral
entri
bare
inhibit
zikv
infect
viral
postentri
stage
result
consist
timeofaddit
assay
show
inhibitori
activ
eryest
earli
stage
howev
azi
target
postentri
stage
viral
life
cycl
exhibit
differ
inhibitori
mechan
eryest
viral
entri
consist
variou
process
includ
viral
attach
fusion
develop
separ
experi
explor
inhibitori
mechan
eryest
show
eryest
significantli
obstruct
attach
zikv
overal
result
suggest
eryest
may
entri
inhibitor
zikv
mainli
suppress
process
attach
inhibitori
stage
differ
macrolid
antibiot
may
vari
wide
studi
inhibitori
mechan
eryest
demonstr
mainli
obstruct
zikv
attach
impli
eryest
may
bind
viral
particl
reduc
infect
thu
investig
whether
eryest
could
inactiv
zikv
directli
use
separ
treat
zikv
virion
free
eryest
incub
zikv
eryest
eri
previous
describ
infect
treat
zikv
detect
plaqu
assay
result
show
eryest
decreas
infect
zikv
dosedepend
manner
effect
concentr
eri
show
inactiv
activ
zikv
figur
addit
mosquitoborn
flavivirus
denv
ii
yfv
also
use
verifi
inactiv
effect
eryest
shown
figur
e
eryest
potent
inactiv
denv
ii
yfv
effect
concentr
respect
data
indic
eryest
inhibit
viru
infect
directli
inactiv
viral
particl
report
zikv
inhibitor
human
breast
milk
could
inactiv
viru
particl
destruct
integr
zikv
use
similar
approach
investig
whether
eryest
inactiv
zikv
induc
releas
genom
rna
virion
rnase
digest
assay
found
genom
rna
untreat
zikv
eryest
treat
eri
protect
rnase
digest
rna
zikv
treat
eryest
digest
dosedepend
manner
figur
g
impli
reduct
genom
rna
insid
integr
viral
particl
genom
rna
digest
rnase
treatment
eryest
illustr
eryest
may
caus
releas
genom
rna
inactiv
zikv
virion
next
confirm
potenti
inactiv
mechan
zikv
media
alon
respect
treat
eryest
eri
dmso
triton
centrifug
sucros
densiti
gradient
previous
describ
western
blot
use
measur
e
protein
zikv
fraction
four
treat
group
rtqpcr
use
genom
rna
detect
percent
analysi
fraction
zikv
e
protein
genom
rna
eri
dmso
zikv
media
alon
group
consist
distribut
fourth
sixth
fraction
eryest
triton
group
separ
e
protein
mainli
concentr
first
fraction
genom
rna
almost
distribut
fourth
sixth
fraction
figur
impli
destruct
viral
integr
result
indic
eryest
may
inhibit
zikv
infect
destruct
viral
integr
result
releas
genom
rna
result
vitro
demonstr
eryest
display
signific
antizikv
activ
protect
effici
eryest
vivo
estim
establish
transgen
type
interferon
receptordefici
mous
model
zikv
lethal
challeng
eryest
eri
test
concentr
mgkg
day
consecut
day
viral
rna
load
sera
measur
dpi
rtqpcr
shown
figur
viremia
detect
dpi
consider
reduc
mice
eryest
treatment
impli
may
present
better
clinic
statu
continu
observ
found
zikvinfect
mice
treat
eri
vehicl
die
within
dpi
sever
clinic
neurolog
symptom
includ
limb
weak
paralysi
tremor
fortun
mice
treat
eryest
protect
statist
signific
comparison
vehicl
group
figur
surviv
mice
develop
obviou
neurolog
symptom
besid
mice
treat
eryest
gener
kept
good
weight
mainten
growth
figur
show
lighter
clinic
sign
figur
compar
mice
eri
vehicl
treatment
mice
mock
control
group
good
condit
result
suggest
eryest
effici
protect
mice
zikvassoci
neurolog
sign
mortal
gener
consecut
treatment
eryest
show
consider
antizikv
activ
although
play
inhibitori
role
earli
stage
possibl
inactiv
zikv
virion
newli
produc
bodi
suppress
infect
target
cell
reduc
mice
eryest
treatment
impli
may
present
better
clinic
statu
continu
observ
found
zikvinfect
mice
treat
eri
vehicl
die
within
dpi
sever
clinic
neurolog
symptom
includ
limb
weak
paralysi
tremor
fortun
mice
treat
eryest
protect
statist
signific
comparison
vehicl
group
figur
surviv
mice
develop
obviou
neurolog
symptom
besid
mice
treat
eryest
gener
kept
good
weight
mainten
growth
figur
show
lighter
clinic
sign
figur
compar
mice
eri
vehicl
treatment
mice
mock
control
group
good
condit
result
suggest
eryest
effici
protect
mice
zikvassoci
neurolog
sign
mortal
gener
consecut
treatment
eryest
show
consider
antizikv
activ
although
play
inhibitori
role
earli
stage
possibl
inactiv
zikv
virion
newli
produc
bodi
suppress
infect
target
cell
determin
whether
eryest
could
block
vertic
transmiss
zikv
pregnant
mice
infect
izikv
mock
infect
control
pfu
zikv
describ
previous
follow
treatment
eryest
mgkg
eri
mgkg
vehicl
respect
demonstr
viraemia
mice
treat
eryest
reduc
statist
signific
comparison
group
eri
vehicl
treatment
figur
meanwhil
viral
load
zikv
placenta
fetal
head
pregnant
mice
eryest
treatment
significantli
lower
mice
eri
vehicl
treatment
figur
c
besid
infect
rate
placenta
fetal
head
decreas
eryest
treatment
result
suggest
eryest
may
directli
inactiv
zikv
virion
penetr
placenta
fetu
thu
reduc
infect
rate
placenta
fetus
well
block
vertic
transmiss
zikv
pregnant
mice
significantli
lower
mice
eri
vehicl
treatment
figur
c
besid
infect
rate
placenta
fetal
head
decreas
eryest
treatment
result
suggest
eryest
may
directli
inactiv
zikv
virion
penetr
placenta
fetu
thu
reduc
infect
rate
placenta
fetus
well
block
vertic
transmiss
zikv
pregnant
mice
consider
worldwid
attent
recent
zikv
outbreak
mani
effort
made
explor
potenti
effect
therapi
current
approv
practic
prophylact
vaccin
elimin
aed
main
vector
zikv
remain
primari
prevent
measur
high
throughput
screen
alreadyapprov
drug
carri
provid
antizikv
drug
candid
use
method
found
potent
inhibitor
eryest
zikv
studi
eryest
demonstr
inhibit
zikv
infect
dosedepend
manner
plaqu
assay
figur
c
figur
b
also
shown
eryest
could
still
suppress
viral
growth
exhibit
inhibitori
activ
zikv
infect
even
rel
higher
viral
dose
figur
b
treatment
eryest
decreas
viral
titer
approxim
figur
report
peak
concentr
eryest
plasma
multipl
dose
indic
eryest
could
exert
antivir
activ
reliev
viremia
patient
infect
zikv
eryest
one
macrolid
antibiot
block
protein
synthesi
bacteria
mainli
use
staphylococcu
aureu
infect
divers
bacillosi
best
knowledg
antizikv
effect
eryest
previous
evalu
time
studi
besid
macrolid
antibiot
azithromycin
ivermectin
previous
found
effect
inhibit
zikv
infect
moreov
azithromycin
report
inhibit
zikv
vitro
also
prevent
zikvinduc
lethal
suckl
mous
model
interestingli
inhibitori
mechan
differ
macrolid
antibiot
vari
eryest
azi
paper
figur
probabl
caus
differ
effect
viral
particl
host
cell
due
differ
structur
research
macrolid
antibiot
exhibit
differ
inhibitori
mechan
zikv
need
effect
macrolid
divers
characterist
advantag
constantli
discov
opportun
research
clinic
treatment
provid
clinic
dosag
eryest
adult
gday
accord
drug
instruct
report
safe
use
pregnant
women
dosag
gday
assess
whether
antibiot
treatment
could
benefit
pregnant
women
heavi
vagin
ureaplasma
colon
sinc
consid
safe
pregnant
women
eryest
could
provid
choic
zikvinfect
gravida
like
suffer
seriou
consequ
abort
prematur
birth
babi
microcephali
meanwhil
sexual
transmiss
zikv
constantli
report
eryest
also
show
great
potenti
develop
microbicid
antizikv
bactericid
effect
would
block
sexual
transmiss
zikv
would
conduc
healthi
vagin
environ
safeti
profil
eryest
pregnant
women
vagin
use
thu
increas
clinic
option
treatment
prevent
zikv
infect
moreov
eryest
demonstr
protect
vertic
transmiss
zikv
pregnant
mice
indic
may
good
effect
decreas
fetal
infect
risk
reduc
fetal
symptom
use
infect
pregnant
women
studi
besid
inhibitori
activ
differ
zikv
strain
eryest
also
demonstr
potent
inhibit
mosquitoborn
flavivirus
includ
denv
yfv
present
opportun
clinic
applic
patient
may
suffer
coinfect
zikv
denv
epidem
area
viral
vector
aed
aegypti
preval
moreov
report
preexist
denv
antibodi
may
aggrav
zikv
infect
antibodydepend
enhanc
ade
effect
phenomenon
certain
antibodi
promot
entri
heterogen
virus
host
cell
modif
therapeut
antibodi
may
decreas
risk
ade
rel
increas
cost
antibodi
eryest
inhibitori
activ
broad
spectrum
flaviviru
may
afford
choic
patient
simultan
infect
without
risk
ade
effect
present
mani
micromolecular
inhibitor
target
viral
bind
endocytosi
replic
zikv
discov
suppress
activ
effect
viru
attach
enter
replic
insid
target
cell
studi
inhibitori
mechan
paper
eryest
demonstr
directli
inactiv
flaviviru
zikv
denv
yfv
specul
probabl
interact
conserv
sequenc
envelop
protein
flavivirus
first
destabil
envelop
protein
lipid
viral
membran
consequ
integr
viral
membran
disrupt
result
loss
viral
infect
detail
inactiv
mechan
eryest
remain
studi
futur
eryest
viral
inactiv
like
synthet
peptid
deriv
zikv
envelop
protein
make
possibl
effect
inhibit
zikv
viral
entri
therefor
benefici
treat
infector
viremia
viral
inactiv
hand
promptli
work
contact
viru
may
directli
reduc
viral
load
target
cell
likewis
eryest
may
prevent
influx
virion
fetus
accordingli
combin
therapi
eryest
inhibitor
differ
inhibitori
stage
zikv
may
synergist
effect
improv
protect
conclus
eryest
one
macrolid
antibiot
exhibit
power
antizikv
effect
vitro
vivo
show
excel
safeti
indic
could
repurpos
novel
antivir
drug
treat
zikv
infect
popul
high
risk
particularli
pregnant
women
supplementari
materi
follow
avail
onlin
http
figur
inhibit
eryest
zikv
vero
cell
assay
figur
inhibit
eryest
zikv
multipl
round
infect
inhibitori
activ
eryest
high
dose
infect
zikv
figur
inhibit
eryest
zikv
vzikv
prepar
vero
cell
author
contribut
pz
conceiv
design
experi
xw
perform
experi
analyz
data
sx
assist
xw
analyz
data
xw
wrote
origin
draft
pz
review
edit
paper
